Neoplasms

All Conditions

Eye Diseases

Carcinoma

Carcinoma, Squamous Cell

Conjunctival Neoplasms

Eye Neoplasms

Conjunctival Diseases

Antineoplastic Agents

All Drugs and Chemicals

Coagulants

Mitomycins

Mitomycin

Fibrin Tissue Adhesive

Excision of the conjunctival tumour was done.Amniotic membrane was secured into conjunctival defects. Postoperative topical MMC 0.04% was given. Response to treatment was monitored clinically and by AS-OCT.

Treatment of diffuse ocular surface squamous neoplasia

A prospective study was performed on 8 eyes of 8 patients who underwent amniotic membrane graft after diffuse conjunctival squamous cell neoplasia excision followed by topical mitomycin C 0.04% eye drop between March 2014 and January 2018.

Surgical excision of the conjunctival tumour . A superficial corneal scraping was performed for corneal lesion then double freeze-thaw cryotherapy was applied to limbal edge and conjunctival margins.The amniotic membrane graft was secure and attached to the sclera and conjunctiva using ﬁbrin glue.Topical mitomycin C 0.04%eye drop was prescribed 4 times daily per treatment cycle (1 cycle=1 week on 1 week off).

AS-OCT Guided Treatment of Diffuse CSCC

Anterior Segment Optical Coherence Tomography (AS-OCT) Guided Treatment of Diffuse Conjunctival Squamous Cell Carcinoma (CSCC) With Excision, Amniotic Membrane Graft Using Fibrin Glue and Topical Mitomycin C (MMC)

Any recurrence which is detected clinically or/and by AS-OCT

Benha University

lecturer of ophthalmology

Musculoskeletal Diseases

Orbital Neoplasms

Skull Neoplasms

Bone Neoplasms

Bone Diseases

Orbital Diseases

Develop an intelligent screening system for ocular surface malignant tumors, apply it to the mobile terminal for real-world verification and large-scale general screening, and test its effect on assisting doctors in the diagnosis and treatment of rare diseases.

screening system for ocular surface malignant tumors

Haotian Lin, M.D., Ph.D

Ruixin Wang, M.D., Ph.D

Rare diseases generally refer to diseases whose prevalence rate is lower than 1 / 10 000 and the number of patients is less than 140000. Rare diseases are generally faced with the dilemma of a lack of qualified doctors, difficulty in large-scale screening, and a lack of rapid and effective channels for medical treatment. Studies have shown that 42% of patients say they have been misdiagnosed, and each patient with a rare disease needs to go through an average of eight doctors in seven years to see a corresponding rare disease specialist. More importantly, most rare diseases seriously affect the health and quality of life of patients. The ocular surface malignant tumor is a typical rare disease, and its incidence is less than 1 / 100000. The ocular surface not only affects the patient's appearance, but also damages the visual function, and the malignant tumor may even affect life. These uncommon malignant tumors are often hidden in the common black nevus on the eye surface, which is easy to be ignored and has great potential risks. With the improvement of people's living standards, people start to pay attention to rare diseases.

In recent years, the rapid development of digital technology has also provided new opportunities for the prevention and treatment of rare diseases. Our team established the database of rare ophthalmopathy in China in the early stage, which provided a solid foundation for the digitization of precious clinical data. This study intends to develop an intelligent screening system for ocular surface malignant tumors, using the mobile phone for real-world verification and scale screening, and explore it to improve the ability of doctors to diagnose and treat rare diseases. This study is expected to improve the ability to screen malignant tumors on the ocular surface and provide a novel model for the universal screening of rare diseases.

Artificial Intelligence-assisted Screening of Malignant Pigmented Tumors on the Ocular Surface

Measure of the ability of a binary classifier to distinguish between malignent and benign.

The study will assess the sensitivity and specificity of the CaptureTumor (CaT) system under various conditions.

Count the number of people who have successfully received and read knowledge about ocular surface pigmented tumors on each offline and online platform.

For cases where the system judges that it is necessary to go to the hospital for further diagnosis and treatment, two or more researchers will conduct a diagnostic review first. If further diagnosis and treatment is really needed, the subject will be contacted and told to go to the hospital for treatment by phone, text message, etc., and continue to follow up. Finally, the duration of diagnosis (screening time to pathological diagnosis time), visit distance, number of visits before diagnosis, and the proportion of referred patients in all subjects were counted.

Doctors with different seniority were asked to diagnose the test set with and without assistance from the intelligent screening system, and the accuracy in the two cases were calculated and compared.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
AS-OCT Guided Treatment of Diffuse CSCC	NCT03515954	Conjunctival Ne...	Treatment of di...	18 Years -	Benha University
AS-OCT Guided Treatment of Diffuse CSCC	NCT03515954	Conjunctival Ne...	Treatment of di...	18 Years -	Benha University
Artificial Intelligence-assisted Screening of Malignant Pigmented Tumors on the Ocular Surface	NCT05645341	Orbital Neoplas... Conjunctival Ne... Eye Neoplasms	screening syste...	-	Sun Yat-sen University

Spots Global Cancer Trial Database for conjunctival neoplasms